Get the Stockscreener App
1.27
0.79%
0.01
Pre-market:
1.25
-0.02
-1.57%
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Sangamo reports positive Fabry disease gene therapy results - MSN
Sangamo reports updated data for gene therapy candidate ST-920 - Seeking Alpha
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - BioSpace
Sangamo reports positive Fabry disease gene therapy results By Investing.com - Investing.com UK
Revolutionary Fabry Disease Treatment Eliminates Need for Enzyme Therapy in All Patients - StockTitan
Sangamo Therapeutics (NASDAQ:SGMO) delivers shareholders stellar 160% return over 1 year, surging 12% in the last week alone - Simply Wall St
Golden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat
HC Wainwright Has Bearish Forecast for SGMO FY2024 Earnings - MarketBeat
Research Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc.SGMO - The Eastern Progress Online
Sangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC Wainwright - Defense World
Sangamo Therapeutics' (SGMO) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts - Benzinga
Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Truist Financial Has Lowered Expectations for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $5.17 - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Truist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00 - MarketBeat
Sangamo Therapeutics Stock Slips On Termination of Pfizer Collaboration: Retail’s Cautious - MSN
Sangamo Nearing Fabry Gene Therapy Deal To Fund Its Pipeline - Citeline News & Insights
Top 5 NASDAQ Genetics Stocks (Updated January 2025) - Nasdaq
Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Shareholders to Inquire about Securities Investigation - AccessWire
Sangamo Q3 2018 First Look: Dancing With Data (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal - MSN
Sangamo Therapeutics Shares Plunge 50% After Pfizer Pulls Out of Hemophilia Drug Deal – Market - HPBL
WASATCH ADVISORS LP Reduces Stake in Sangamo Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sangamo Therapeutics, Inc. (SGMO) Stockholders to Inquire about Securities Investigation - AccessWire
15 Small-Cap Stocks Poised to Outperform in 2025 - Insider Monkey
Sangamo to regain rights to hemophilia A gene therapy - Hemophilia News Today
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sangamo Therapeutics, Inc. (SGMO) And Encourages Stockholders to Connect - AccessWire
Hemoglobinopathies Market Projected to Show Strong Growth| - openPR
Sangamo Therapeutics, Inc. (SGMO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
State Street Corp Grows Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More - Zacks Investment Research
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):